Compare REE & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REE | LNAI |
|---|---|---|
| Founded | 2011 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 20.6M |
| IPO Year | N/A | N/A |
| Metric | REE | LNAI |
|---|---|---|
| Price | $0.67 | $0.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.75 | N/A |
| AVG Volume (30 Days) | 132.2K | ★ 182.3K |
| Earning Date | 03-16-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $207,000.00 | N/A |
| Revenue This Year | $327.73 | N/A |
| Revenue Next Year | $36,888.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $0.79 |
| 52 Week High | $9.53 | $14.00 |
| Indicator | REE | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 37.14 | 40.06 |
| Support Level | $0.69 | $0.79 |
| Resistance Level | $0.78 | $0.97 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 21.31 | 27.02 |
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.